NeuroSigma Announces FDA Clearance of its Second-Generation
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s...
Source: globenewswire.com
📰 C Thomas Paschall News
C Thomas Paschall News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from C Thomas Paschall. Real-time updates on events, politics, business and more.
NeuroSigma Announces HSA Approval of the Monarch eTNS System in Singapore
LOS ANGELES, Oct. 03, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced approval of the Monarch eTNS System by Singapore’s Health Sciences Authority (HSA), the national body that regulates medical devices, therapeutics, and other healthcare products. The Monarch external Trigeminal Nerve Stimulation (eTNS) System is indicated for treatment of pediatric attention deficit hyperactivity disorder (ADHD) as a monotherapy for patients ages 7 through 12 years old who are not currently taking p...
United States Los Angeles Colin Kealey C Thomas Paschall Singapore Health Sciences Authority Checkmate Capital Group
Source: yahoo.com
Ignis Therapeutics Licenses NeuroSigma eTNS Technology for ADHD in a Significant China Licensing Transaction
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Source: apnews.com